Theravance Biopharma, Inc.TBPHNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank7
3Y CAGR-34.9%
5Y CAGR-29.8%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-34.9%/yr
vs -8.8%/yr prior
5Y CAGR
-29.8%/yr
Recent deceleration
Acceleration
-26.1pp
Decelerating
Percentile
P7
Near historical low
vs 5Y Ago
0.2x
Contraction
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$18.52M-73.2%
2024$69.17M-1.8%
2023$70.45M+5.0%
2022$67.07M-
2021$0.00-100.0%
2020$108.53M+2.3%
2019$106.08M+9.3%
2018$97.06M+1.5%
2017$95.59M+13.1%
2016$84.51M-